GMS Becomes The Center Of A $5 Billion Tug-Of-War — Here’s Why Everyone Wants In!
GMS Inc., a leading building products distributor based in Tucker, Georgia, has suddenly found itself at the center of a bidding war between Home Depot and QXO Inc.
Micron Rises on Strong Earnings, But AI Growth Expectations Keep Investors Cautious
One of the top-performing chipmakers of 2025, Micron Technology Inc. (NASDAQ: MU), had a mixed reaction from investors following its latest quarterly earnings report and outlook for the upcoming quarter.
Stock Market Today: Market Rally Continues as Investor Optimism Picks Up
US stocks are trading strongly today, continuing their rally as the S&P 500 inches closer to a record high.
Caterpillar Isn’t Just About Bulldozers Anymore—It’s Fueling Data Centers!
Caterpillar has slowly emerged as a key player in the energy sector—this time not because of construction equipment, but thanks to its strategic play in powering AI data centers.
Microsoft on the Brink: What a Split With OpenAI Means for the Future of AI!
The once-symbiotic relationship between Microsoft and OpenAI is showing severe signs of strain, raising concerns about the future of one of the most high-profile alliances in the AI space.
Peloton’s Bold Reset: Can New Hires & Smarter Spending Power A Comeback?
Peloton has hired a new leadership team and new CEO Peter Stern is implementing a multi-pronged turnaround strategy that targets cost reduction, new revenue channels, and improved customer retention.
Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!
Eli Lilly has expanded into cardiovascular treatment with its $1.3 billion acquisition of Verve Therapeutics, a clinical-stage gene-editing company focused on one-time therapies to lower cholesterol and prevent heart disease.